BDBM111122 US10017516, Compound 17::US9682983, 1::US9682983, 17

SMILES C1CN(CCN1)c1ccc(cn1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12

InChI Key InChIKey=YTUZELSDHUVEFM-UHFFFAOYSA-N

Data  22 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 22 hits for monomerid = 111122   

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 83nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 229nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 6.49E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 146nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 40nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 112nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.25E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.06E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.70E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 864nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 83nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 229nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 6.49E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 146nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 40nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 112nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.25E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.06E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 2.70E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 864nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 29nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In DepthDetails
US Patent